Radioimmunotherapy (RIT) is often used as an adjuvant therapy or consolidation therapy for cancer due to its relative high specificity and minimized radiation damage to non-targeted organs.The progress of RIT in solid tumors was slow,however,it has been developed quickly recently especially in elimination of residual micro-tumor lesions due to the application of α radionuclide,the progress in antibody preparation,and the implementation of new therapeutic strategies.